Foghorn Therapeutics Inc. (NASDAQ:FHTX) shares are trading lower by 8.49% to $4.85 during Monday's session after the company announced it will discontinue independent development of its FHD-286 program in combination with decitabine for relapsed/refractory acute myeloid leukemia (AML) due to insufficient response rates in a Phase 1 trial.

What To Know: While Foghorn says clinical responses were observed, the results did not meet the company's threshold for continuation. Results from the trial will be presented at a medical conference in 2025.

Read Also: Honeywell Advances Strategic Review, Explores Aerospace Business Separation

The company says it will prioritize its proprietary programs, including Selective CBP, Selective EP300 and ARID1B, along with its Lilly collaboration, which includes the development of FHD-909. Partnerships and Investigator Sponsored Trials are being considered to further advance FHD-286.

Foghorn reported $267.4 million in cash and equivalents as of September 30, 2024, providing a cash runway into 2027. CEO Adrian Gottschalk emphasized the potential of the company's innovative oncology pipeline and expressed gratitude to trial participants.

AML, the focus of the discontinued trial, is a blood and bone marrow cancer diagnosed in 20,000 U.S. adults annually.

Read Also: U.S. Stocks To Open Higher Ahead Of Fed's Decision This Week: Analyst Says 'Santa Comes Later In December'

Should I Sell My FHTX Stock?

Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.

Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.

Shares of Foghorn Therapeutics (NASDAQ:FHTX) have lost 1.67% year to date. This compares to the average annual return of -33.39%, meaning the stock has outperformed its historical averages. Investors can compare a stock's movement to its historical performance to gauge whether this is a normal movement or a potential trading opportunity.

Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Foghorn Therapeutics stock currently has an RSI of 1.18, indicating oversold conditions.

For analysis tools, charting data and access to exclusive stock news, check out Benzinga PRO. Try it for free.

FHTX has a 52-week high of $10.25 and a 52-week low of $2.70.